Cognition Therapeutics CEO to Discuss Key Trials at B. Riley Summit
Event summary
- Cognition Therapeutics CEO Lisa Ricciardi to participate in a fireside chat at B. Riley's Mind, Muscle & Vision Summit on July 16, 2026.
- Discussion will cover the START study and planned Phase 3 trial for zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.
- Zervimesine has shown promise in Phase 2 trials for DLB and Alzheimer’s disease, with $200M in NIH funding supporting its development.
The big picture
Cognition Therapeutics is positioning itself as a key player in the neurodegenerative disease space, with zervimesine (CT1812) representing a potential breakthrough therapy. The company's focus on leveraging well-established biological pathways and its substantial NIH funding highlight its strategic advantage in developing novel treatments for conditions like DLB and Alzheimer’s disease.
What we're watching
- Trial Execution
- How the START study results will influence the planned Phase 3 trial for zervimesine in DLB psychosis.
- Regulatory Pathway
- Whether the strong efficacy signals observed in Phase 2 trials will translate into successful late-stage clinical outcomes.
- Market Opportunity
- The pace at which Cognition Therapeutics can capitalize on the unmet need in DLB and Alzheimer’s disease markets.
Related topics